Revelation Biosciences (REVB) Total Non-Current Liabilities (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Total Non-Current Liabilities of $1.9 million for Q3 2025, down 54.35% year-over-year from $4.1 million in Q3 2024, and up 18.22% quarter-over-quarter from $1.6 million in Q2 2025.
Revelation Biosciences (REVB) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Total Non-Current Liabilities for 5 consecutive years, with $1.9 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 54.35% year-over-year to $1.9 million; the TTM figure through Sep 2025 stood at $1.9 million (down 54.35% YoY), while the FY2024 annual figure was $1.9 million, down 64.76% from the prior year.
- Total Non-Current Liabilities grew to $1.9 million in Q3 2025 per REVB's latest filing, from $1.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $11.1 million in Q2 2024 and bottomed at $1.1 million in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged $4.0 million across 4 years, with a median of $4.2 million in 2023.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 157.25% — and 2025, when it plunged 85.89%.
- Revelation Biosciences' Total Non-Current Liabilities stood at $1.1 million in 2021, then jumped by 379.09% to $5.4 million in 2023, then slumped by 64.76% to $1.9 million in 2024, then dropped by 2.99% to $1.9 million in 2025.
- Business Quant data shows REVB's Total Non-Current Liabilities at $1.9 million in Q3 2025, $1.6 million in Q2 2025, and $1.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | Revelation Biosciences | 4.14 Mn | -7.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 11.12 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 5.42 Mn |
| Sep 30, 2023 | 5.19 Mn |
| Jun 30, 2023 | 4.32 Mn |
| Mar 31, 2023 | 4.59 Mn |
| Dec 31, 2021 | 1.13 Mn |
| Dec 31, 2020 | 2.95 Mn |